<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="342">
  <stage>Registered</stage>
  <submitdate>31/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000280606</actrnumber>
  <trial_identification>
    <studytitle>Isocapnic intermittent hypoxia and endothelial dysfunction</studytitle>
    <scientifictitle>The effects of nitric oxide synthase inhibition on arterial stiffness during short term hypoxic exposure in healthy men</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Sydney South West Area Health Service Ethic Committee: X03-0093</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy control subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will be infused with L-N monomethyl arginine (LNMMA) and saline (placebo) in a single blinded randomized design on two separate days to assess the effect of nitric oxide synthase inhibition on arterial stiffness.    Initially there will be a 10 minute baseline period. Then the LNMMA or saline will be infused over 5 minutes, after which there will be another 5 minute baseline period.  Following this there will be the 20 minute period of hypoxia and then a 10 minute recovery period.  During this the subjects will breathe through a mouthpiece connected to special equipment which delivers different gas mixtures and enables the delivery of the hypoxic exposure. Heart rate blood pressure, arterial stiffness ( via pulse wave analysis), and peripheral vasoconstriction (via peripheral arterial tonometry PAT) will be measured.</interventions>
    <comparator>Saline (placebo)</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To measure the effect of LNMMA, a nitric oxide synthase inhibitor, on the change in AIx (an index of arterial stiffness), with hypoxic exposure</outcome>
      <timepoint>Measured continuously during the 50 minute protocol.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in heart rate</outcome>
      <timepoint> This will be measured continously during the 50 minute protocol.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in blood pressure</outcome>
      <timepoint> This will be measured continously during the 50 minute protocol.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in peripheral arterial tonometry</outcome>
      <timepoint> This will be measured continously during the 50 minute protocol.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in ventilation with hypoxic exposure.</outcome>
      <timepoint> This will be measured continously during the 50 minute protocol.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy men</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of obstructive sleep apnoea  or cardiovascular or respiratory disease, Smoker,  Treatment with cardiovascular or respiratory medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>Computer program to generate random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/05/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>NHMRC</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Hima Vedam</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 404072392</phone>
      <fax />
      <email>himav@mail.med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>wtaylor@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>